These differences could influence the choice of peptide in formulations targeting specific wound healing applications
Who Can Use the 96372 CPT Code
Whether you're a health enthusiast or someone curious about optimizing your health, youll find valuable information here to get you started
Administration Codes: CPT 96372 - Therapeutic/prophylactic/diagnostic injection, subcutaneous or intramuscular (in-office administration) Modifier 59/XS - For additional separate injections on same date Modifier 25 - On E/M code when separate E/M service performed same day as injection Drug Codes (HCPCS): J3490 - Unclassified drugs (primary code for tirzepatide in physician office) C9399 - Unclassified drugs or biologicals (hospital outpatient setting) J3590 - Unclassified biologics (alternative, less commonly used) J3420 - Injection, vitamin B-12 cyanocobalamin, up to 1000 mcg (when B12 billed separately) Diabetes Diagnosis Codes (Mounjaro): E11.65 - Type 2 diabetes with hyperglycemia (strongest for medical necessity) E11.9 - Type 2 diabetes without complications E11.21 - Type 2 diabetes with diabetic nephropathy E11.40 - Type 2 diabetes with diabetic neuropathy Z79.85 - Long-term (current) use of injectable non-insulin antidiabetic drugs Obesity Diagnosis Codes (Zepbound): E66.01 - Morbid (severe) obesity due to excess calories E66.09 - Other obesity due to excess calories E66.3 - Overweight Z68.30-Z68.45 - BMI codes (required supplemental codes) Common Comorbidity Codes: I10 - Essential hypertension E78.5 - Hyperlipidemia, unspecified G47.33 - Obstructive sleep apnea K76.0 - Fatty liver, not elsewhere classified (NAFLD) M19.90 - Unspecified osteoarthritis E/M Codes: 99203-99205 - New patient office visits 99213-99215 - Established patient office visits G0447 - Face-to-face behavioral counseling for obesity, 15 min (Medicare) Counseling and Therapy Codes: 99401-99404 - Preventive medicine counseling 97802 - Medical nutrition therapy, initial assessment 97803 - Medical nutrition therapy, reassessment This reference table covers the vast majority of coding scenarios for tirzepatide
The following adverse event rates were reported at any time following initial injection and prior to reinjection or study exit (median duration of 44 weeks of exposure): UTIs (49%), urinary retention (17%), constipation (4%), muscular weakness (4%), dysuria (4%), fall (3%), gait disturbance (3%), and muscle spasm (2%)
Fast injection creates turbulence
